Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: A cross-sectional study

Klaziena Politiek1 | Robert F. Ofenloch2 | Marius J. Angelino1 | Ewoud van den Hoed1 | Marie L. A. Schuttelaar1

1Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2Department of Dermatology, Occupational Dermatology, University Hospital Heidelberg, Occupational and Environmental Dermatology, Heidelberg, Germany

Correspondence
Dr Marie L. A. Schuttelaar, Department of Dermatology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
Email: m.l.a.schuttelaar@umcg.nl

Abstract
Background: Recurrent vesicular hand eczema frequently has a chronic course and needs long-term treatment.
Objectives: To evaluate health-related quality of life (HRQoL), treatment satisfaction, and adherence in patients with vesicular hand eczema.
Methods: Patients using one main treatment for at least three months were included. Data on HRQoL (Quality of Life in Hand Eczema Questionnaire [QOLHEQ]), treatment satisfaction (Treatment Satisfaction Questionnaire for Medication, version II), and treatment adherence (4-item Morisky Medication Adherence Scale) were collected. Univariate and multivariate regression analysis were used to predict variables associated with HRQoL.
Results: HRQoL was moderately impaired, with the highest impact in the QOLHEQ subdomain symptoms. Female sex, more severe hand eczema, and lower treatment satisfaction were associated with more impairment in HRQoL. Patients with severe/very severe hand eczema had significant lower "global satisfaction" scores compared with the other severity groups. The "global satisfaction" and treatment adherence in patients using systemic treatment were significantly higher compared with those with only topical treatment.
Conclusions: In patients with vesicular hand eczema disease severity affects both HRQoL and treatment satisfaction. Systemic treatment of severe hand eczema could improve the severity and as a result also HRQoL, treatment satisfaction, and medication adherence.

KEYWORDS
health-related quality of life, patient-reported outcomes, recurrent vesicular hand eczema, treatment adherence, treatment satisfaction
1 | INTRODUCTION

Hand eczema can be classified into different clinical subtypes. Recurrent vesicular hand eczema is a typical clinical subtype that is characterized by development of small (1-2 mm) vesicles most often interdigitally or on the palms. The patient experiences episodes of vesicles mostly at unpredictable intervals, which can result in a chronic course of recurrent vesicular hand eczema. In addition to a clinical diagnosis, it is important to classify hand eczema etiologically. The cause of hand eczema is often multifactorial. It can be classified into one or more of the following etiological diagnoses: allergic contact dermatitis, irritant contact dermatitis (ICD), protein contact dermatitis, and atopic hand eczema.1

The treatment of chronic hand eczema is often challenging and at times insufficient and unsatisfactory.2,3 Studies on treatment effectiveness are mainly based on physician-reported outcomes. Fewer studies have actually evaluated treatment benefit in terms of patient-reported outcomes.4,5 However, chronic hand eczema can have a remarkable impact on quality of life.2,6

To evaluate the impact of disease and treatment on physical, psychological, and social functioning, the Quality of Life in Hand Eczema Questionnaire (QOLHEQ) was recently developed. It measures overall health-related quality of life (HRQoL) impairment in four domains: “symptoms,” “emotions,” “functioning,” and “treatment and prevention.”7,8 Other patient-reported outcomes are treatment satisfaction and treatment adherence.9,10 Previous studies in several therapeutic areas demonstrated a positive association between treatment satisfaction and adherence to therapy.11 In this study we aimed to examine HRQoL, treatment satisfaction, and treatment adherence in patients with recurrent vesicular hand eczema.

2 | METHODS

2.1 | Study design and participants

This cross-sectional study was conducted at the Dermatology Department of the University Medical Center Groningen (Groningen, The Netherlands), a tertiary referral center for hand eczema, between December 2016 and May 2019. Patients were recruited while they were on a routine visit at the outpatient clinic. Despite the fact that some patients had mild contributing atopic dermatitis, hand eczema was the main reason for consultation. Inclusion criteria were adult age (>18 years old), diagnosis of chronic (>3 months) vesicular hand eczema (classification of Menné et al11), and use of at least one main treatment for at least three months. Patients concomitantly treated with bursts of oral corticosteroids in the last 3 months were excluded. Included patients needed to be able to read and understand the Dutch language. Patients were interviewed according to a structured questionnaire. The study was reviewed and approved by the Medical Ethical Review Board of the University Medical Center Groningen (reference METc M17.207552).

2.2 | Clinical characteristics

Data collected were basic characteristics (age, sex, education [low/middle vs high]), employment status (low- vs high-risk occupation for hand eczema15), and elevated total and specific immunoglobulin E inhalant allergens. Etiological hand eczema diagnosis was based on fixed criteria (see Data S1).

Data on current (topical, UV, and systemic treatment) and previous (topical, UV, systemic treatment, and hospitalization) treatments for hand eczema were collected. All patients with vesicular hand eczema were treated according to the Dutch guidelines of hand eczema.13,14 Previous treatment with oral corticosteroids for over 2 weeks was counted as a history of systemic treatment. The current treatment was based on the most potent medication (systemic treatment vs nonsystemic treatment). Patients with systemic treatment may have used concomitantly topical corticosteroids. Disease severity was assessed by the physician with the photographic guide of Coenraads et al.15 For a complete overview of all variables, see the questionnaire in Data S1.

2.3 | Quality of life, treatment satisfaction, and adherence

To evaluate the HRQoL, the Dutch translation of the QOLHEQ was used, range 0-89. This disease-specific questionnaire consists of 30 questions covering four subdomains: “symptoms” (7 questions), “emotions” (8 questions), “functioning” (8 questions), and “treatment and prevention” (7 questions). Response categories are never, rarely, sometimes, often, and always.7,8 For the recently validated Dutch language version, these are scored as 0, 1, 2, and 3, respectively. The severity band for the QOLHEQ overall score for Dutch patients is as follows: not at all, 0-13; slightly, 14-28; moderately, 29-44; strongly, 45-64; and very strongly, ≥65.16

Satisfaction was assessed with the Dutch version of the Treatment Satisfaction Questionnaire for Medication, version II (TSQM-II), range 0-100.9 The TSQM-II is an 11-item validated questionnaire comprising three domains: “effectiveness” (2 questions), “side effects” (4 questions), and “convenience” (3 questions). Moreover, “global satisfaction” (2 questions) was measured. Response categories are as follows: 1, extremely dissatisfied; 2, very dissatisfied; 3, dissatisfied; 4, somewhat satisfied; 5, satisfied; 6, very satisfied; and 7, extremely satisfied. The score per domain can be calculated with an algorithm ranging from 0 to 100, where higher scores equate to better outcomes.

To evaluate treatment adherence four dichotomous questions (yes [1]/no [0]), the 4-item Morisky Medication Adherence Scale was used, range 0-4. A sum score of 0 represents a high patient adherence, a score of 1 or 2 represents a medium adherence, and a score of 3 or 4 represents a low adherence.10
2.4 Statistical analyses

Data analyses were performed using IBM SPSS Statistics version 23.0 for Windows (SPSS/IBM, New York, New York). Descriptive statistics were presented as mean together with median and range for interval-scaled variables, and as relative frequency together with absolute numbers for categorical variables. The four QOLHEQ and TSQM subdomains were analyzed separately for the group of patients with non-systemic therapy and for the group with systemic therapy. After controlling for normal distribution, the independent sample t test was used to analyze the differences in treatment satisfaction and HRQoL between both treatment groups. Fisher’s exact test was used to test difference in nominal variables between the nonsystemic and systemic groups. Univariate regression analysis included as independent variables age, gender, level of education (high vs middle/low), duration of hand eczema (years), the current treatment (nonsystemic vs systemic treatment), hand eczema severity, treatment adherence, and “global satisfaction,” which were suitable for inclusion (P < .2) into the multivariate regression model. Afterwards, multivariate linear regression was used including clinical characteristics associated with treatment satisfaction. P-values less than .05 were considered statistically significant in all analyses. Standardized β-coefficients were presented, with strong correlation defined as β > 0.7, moderate correlation as 0.7 > β > 0.4, and weak correlation as 0.4 > β > 0.2.17 The interpretability of the Dutch and International QOLHEQ (subdomain and overall) scores was published by Oosterhaven et al.8,16 See Data S3 for the Dutch (Table S3.3) and International (Table S3.4) single score bands. In this publication Dutch scores were presented; the International scores can be found in Data S3.

3 RESULTS

In total, 168 (56.0% female) participants were included in this study. Sociodemographic and clinical characteristics are outlined in Table 1. The mean duration (median [range]) of a diagnosis of hand eczema

| Characteristics                                      | All patients | Male | Female | Nonsystemic treatment | Systemic treatment |
|-------------------------------------------------------|--------------|------|--------|-----------------------|-------------------|
| Number of patients, n (%)                             | 168 (100)    | 74 (44.0) | 94 (56.0) | 112 (100)             | 56 (100)          |
| Age (years), mean (SD)                                | 43.1 (15.7)  | 44.4 (14.4) | 42.0 (16.6) | 67 (59.8)             | 27 (48.2)         |
| High education, n (%)                                 | 35 (20.8)    | 15 (20.3)  | 20 (21.3) | 40.0 (15.6)*           | 49.3 (14.1)*      |
| High-risk occupation, n (%)                           | 63 (37.5)    | 30 (40.5)  | 33 (35.1) | 27 (24.1)*             | 8 (14.3)*         |
| Duration of hand eczema (years), mean (SD)            | 9.2 (11.3)   | 10.1 (11.8) | 8.5 (10.9) | 48 (42.9)             | 17 (30.4)         |
| Elevated total IgE level (>115 kU/L), n (%)           | 41 (37.6)*   | 21 (41.2)* | 20 (34.5) | 7.5 (9.9)*             | 12.5 (13.3)*      |
| Elevated serum-specific IgE inhaled allergens, n (%)  | 52 (50.0)*   | 30 (60.0)* | 22 (40.7) | 27 (39.7)             | 14 (34.1)*        |
| Etiological diagnosis*, n (%)                         |              |      |        |                       |                   |
| Atopic hand eczema                                    | 91 (54.2)    | 38 (51.4)  | 53 (56.4) | 56 (50.0)             | 35 (62.5)         |
| Irritant contact dermatitis                            | 81 (48.2)    | 36 (48.6)  | 45 (47.9) | 57 (50.9)             | 24 (42.9)         |
| Allergic contact dermatitis                           | 61 (39.6)*   | 26 (35.1)* | 35 (37.2) | 42 (42.0)*             | 19 (35.2)*        |
| Protein contact dermatitis                            | 0 (0)        | 0 (0)      | 0 (0)     | 0 (0)                  | 0 (0)             |
| Etiologically unclassifiable hand eczema              | 20 (11.9)*   | 8 (10.8)   | 12 (12.8) | 16 (14.3)*             | 4 (7.1)           |
| Current treatment, n (%)                              |              |      |        |                       |                   |
| Only topical treatment*                                | 111 (66.1)   | 45 (60.8)  | 66 (70.2) | 111 (99.1)            | –                 |
| Systemic treatment                                    | 56 (33.3)    | 29 (39.2)  | 27 (28.7) | –                     | 56 (100)          |
| Ciclosporin                                           | 25 (14.9)    | 11 (14.9)  | 14 (14.9) | –                     | 25 (44.6)         |
| Alitretinoin                                          | 12 (7.1)     | 7 (9.5)    | 5 (5.3)   | –                     | 12 (21.4)         |
| Methotrexate                                          | 7 (4.2)      | 3 (4.1)    | 4 (4.3)   | –                     | 7 (12.5)          |
| Dupilumab                                             | 7 (4.2)      | 4 (5.4)    | 3 (3.2)   | –                     | 7 (12.5)          |
| Azathioprine                                          | 4 (2.4)      | 3 (4.1)    | 1 (1.1)   | –                     | 4 (7.1)           |
| Tacrolimus                                            | 1 (0.6)      | 1 (1.4)    | 0 (0)     | –                     | 1 (1.8)           |
| UV therapy                                            | 1 (0.6)      | 0 (0)      | 1 (1.1)   | 1 (0.9)               | –                 |
| Previous treatment, n (%)                             |              |      |        |                       |                   |
| Prior systemic treatment*                              | 65 (38.7)    | 25 (33.8)  | 40 (42.5) | 24 (21.4)*             | 41 (73.2)*        |
| One prior systemic treatment                          | 30 (17.9)    | 9 (12.2)   | 21 (22.3) | 14 (12.5)*             | 16 (28.6)*        |

(Continues)
was 9.2 (11.3 [0.3-65]) years. The severity grades were pooled for the total group (n = 168) because of the small numbers, clear (n = 6) and almost clear (n = 74); severe (n = 31) and very severe (n = 9; Table 1). Female patients had more often clear/almost clear hand eczema compared with male patients, although this was only borderline significant (*P* = .06).

Patch tests were performed in most patients (91.9%, n = 154). Of the patch-tested patients 69.5% (n = 107) had at least one positive patch test reaction to an allergen from the European baseline series. Most patients were patch tested with additional series; 79.2% (n = 122) had at least one positive reaction to allergens from all series tested. Polysensitization was found in 24.0% (n = 37). Of all patients, 37.5% (n = 63) had a high-risk occupation for developing hand eczema. See Data S2 for the list of these occupations. The median (range) treatment duration for nonsystemic and systemic treatments was 0.5 (0.3-32) years and 0.8 (0.3-7) years, respectively.

### 3.1 Health-related quality of life

The overall QOLHEQ scores indicated no impairment of HRQoL in 15.0% of patients (n = 25), slight impairment in 29.8% (n = 50), moderate impairment in 38.1% (n = 64), strong impairment in 12.5% (n = 21), and a very strong impairment in 4.2% (n = 7; Table 2). The mean overall QOLHEQ score was 31.2, representing a moderately impaired HRQoL. The most affected subdomain was "symptoms"; the mean score was 9.1, representing a moderately impaired HRQoL. The other mean QOLHEQ subdomains scores represented slightly impaired HRQoL.

Differences in HRQoL impairment were evaluated for sex and treatment groups. The overall QOLHEQ score and subdomain "functioning" showed moderate impairment in females and slight

| Characteristics                              | All patients | Male          | Female         | Nonsystemic treatment* | Systemic treatment* |
|----------------------------------------------|--------------|---------------|----------------|------------------------|---------------------|
| More than one prior systemic treatment       | 35 (20.8)    | 16 (21.6)     | 19 (20.2)      | 10 (8.9)*              | 25 (44.6)*          |
| Oral corticosteroids (<2 weeks)              | 60 (35.5)    | 29 (39.2)     | 31 (33.0)      | 32 (28.6)*             | 28 (50.0)*          |
| UV therapy                                   | 58 (34.3)    | 23 (31.1)     | 35 (37.2)      | 44 (39.3)              | 14 (25.0)           |
| Previous hospitalization                     | 8 (4.8)      | 3 (4.1)       | 5 (5.3)        | 1 (0.9)*               | 4 (7.1)*            |

### Table 1 (Continued)

- **Clear**
  - Nonsystemic treatment: 6 (3.6)
  - Systemic treatment: 3 (2.7)
  - Overall: 9 (5.4)
- **Almost clear**
  - Nonsystemic treatment: 74 (44.0)
  - Systemic treatment: 48 (51.1)
  - Overall: 122 (73.1)
- **Moderate**
  - Nonsystemic treatment: 48 (28.6)
  - Systemic treatment: 22 (23.4)
  - Overall: 70 (41.8)
- **Severe**
  - Nonsystemic treatment: 31 (18.5)
  - Systemic treatment: 17 (18.1)
  - Overall: 48 (28.6)
- **Very severe**
  - Nonsystemic treatment: 9 (5.4)
  - Systemic treatment: 3 (3.2)
  - Overall: 12 (7.1)

* Abbreviations: IgE, immunoglobulin E; SD, standard deviation.

---

### Table 1

- Characteristics: All patients, Male, Female, Nonsystemic treatment, Systemic treatment
- Nonsystemic treatments included UV therapy, topical corticosteroids always combined with neutral emollients, occasionally with concomitant use of calcineurin inhibitors or tar preparations.
- Systemic treatment included alitretinoin, acitretin, azathioprine, ciclosporin, dupilumab, methotrexate, mycophenolic acid/mycophenolate mofetil, oral corticosteroids (>2 weeks), and tacrolimus.
- Patients can have one or more etiological hand eczema diagnoses.
- 59 patients were not tested.
- 23 patients were not tested.
- 36 patients were not tested.
- 24 patients were not tested.
- 40 patients were not tested.
- 43 patients were not tested.
- 33 patients were not tested.

- 14 patients were not patch tested, necessary for allergic contact dermatitis classification.
- Nine patients were not patch tested, necessary for allergic contact dermatitis classification.
- Five patients were not patch tested, necessary for allergic contact dermatitis classification.
- Twelve patients were not patch tested, necessary for allergic contact dermatitis classification.
- Two patients were not patch tested, necessary for allergic contact dermatitis classification.
- Three patients were not patch tested, necessary for allergic contact dermatitis classification.
- Three patients were not patch tested, necessary for allergic contact dermatitis classification.
- Three patients were not patch tested, necessary for allergic contact dermatitis classification.
- Three patients were not patch tested, necessary for allergic contact dermatitis classification.
- *P < .05, nonsystemic vs systemic treatment.
impairment in males. The HRQoL impairment because of "symptoms" was significantly lower in the group with systemic treatment compared with the group with topical treatment. However, the mean scores in both treatment groups represented moderately impaired HRQoL.

The QOLHEQ overall scores were significantly different between each of the severity groups (P < .001). In the pooled group of patients with severe/very severe hand eczema (mean QOLHEQ overall score 41.1) and the group with moderate hand eczema (mean QOLHEQ overall score 33.3) a moderate impairment of HRQoL was found. The pooled group with clear/almost clear hand eczema (mean QOLHEQ overall score 25.3) showed a slight impairment (Table S3.1-S3.2).

### 3.2 Treatment satisfaction

TSQM subdomain scores are presented in Table 3. Patients were most satisfied about the TSQM subdomain "side effects" and least satisfied about "effectiveness." Patients receiving systemic treatment had significantly higher TSQM treatment satisfaction scores for "effectiveness" and "global satisfaction" compared with patients receiving

---

**TABLE 2** Health-related quality of life impairment assessed with the Quality of Life in Hand Eczema Questionnaire (QOLHEQ) in patients with vesicular hand eczema: interpretation of the overall QOLHEQ score and the QOLHEQ subdomain scores

| Health-related quality of life impairment | Not at all (n, %) | Slightly (n, %) | Moderately (n, %) | Strongly (n, %) | Very strongly (n, %) |
|------------------------------------------|-----------------|----------------|------------------|---------------|-------------------|
| QOLHEQ overall score | 25 (15.0) | 50 (29.9) | 64 (38.3) | 21 (12.6) | 7 (4.2) |
| Symptoms | 2 (1.2) | 60 (35.9) | 48 (28.7) | 45 (26.9) | 12 (7.2) |
| Emotions | 67 (40.1) | 59 (35.3) | 30 (18.0) | 4 (2.4) | 7 (4.2) |
| Functioning | 17 (10.2) | 77 (46.1) | 34 (20.4) | 26 (15.6) | 13 (7.8) |
| Treatment and prevention | 60 (35.9) | 48 (28.7) | 39 (23.4) | 8 (4.8) | 12 (7.2) |

aOne patient missing.

**Abbreviations:** HRQoL, health-related quality of life; MMAS-4, 4-item Morisky Medication Adherence Scale; QOLHEQ, Quality of Life in Hand Eczema Questionnaire; SD, standard deviation; TSQM, Treatment Satisfaction Questionnaire for Medication.

---

**TABLE 3** Means for health-related quality of life impairment (QOLHEQ), treatment satisfaction (TSQM), and treatment adherence (MMAS) for the total group and stratified by sex and type of treatment (systemic vs nonsystemic)

| Characteristics | All patients | Male (n = 74) | Female (n = 94) | All (n = 168) | Nonsystemic treatmenta (n = 112) | Systemic treatmentb (n = 56) |
|-----------------|--------------|--------------|----------------|--------------|---------------------------------|-------------------------------|
| HRQoL impairment (QOLHEQ Dutch subscales), mean (SD)c | Overall score (0-89) | 28.3 (14.4)** | 33.6 (17.8)** | 31.2 (16.5) | 32.5 (16.0) | 28.9 (17.4) |
| Symptoms (0-21) | 8.4 (3.7)* | 9.6 (4.4)* | 9.1 (4.2) | 9.8 (3.8)* | 7.6 (4.5)* |
| Emotions (0-24) | 6.9 (4.7) | 7.8 (5.1) | 7.4 (4.9) | 7.7 (5.0) | 6.9 (4.9) |
| Functioning (0-24) | 6.5 (4.3)** | 8.2 (5.6)** | 7.4 (5.1) | 7.6 (5.0) | 7.1 (5.3) |
| Treatment and prevention (0-20) | 7.3 (4.0)* | 8.8 (4.7)* | 8.1 (4.5) | 8.3 (4.3) | 7.8 (4.7) |
| Treatment satisfaction (TSQM subscale), mean (SD) | Effectiveness (0-100) | 57.2 (17.7) | 60.0 (19.0) | 58.7 (18.4) | 55.9 (17.9)* | 64.4 (18.4)* |
| Side effects (0-100) | 87.0 (21.1) | 88.9 (19.1) | 88.1 (19.9) | 89.3 (20.2) | 85.7 (19.4) |
| Convenience (0-100) | 64.3 (17.1) | 66.7 (12.5) | 65.6 (14.7) | 64.4 (13.0) | 68.1 (17.5) |
| Global satisfaction (0-100) | 61.0 (18.0) | 64.2 (16.2) | 62.7 (17.1) | 60.8 (14.7)* | 66.8 (20.6)* |
| Treatment adherence (MMAS-4), n (%) | High | 18 (24.3)* | 40 (42.6)* | 58 (34.5) | 31 (27.7)* | 27 (48.2)* |
| Medium | 41 (55.4) | 43 (45.7) | 84 (50.0) | 58 (51.8) | 26 (46.4) |
| Low | 15 (20.3) | 11 (11.7) | 26 (15.5) | 23 (20.5) | 3 (5.4) |

Abbreviations: HRQoL, health-related quality of life; MMAS-4, 4-item Morisky Medication Adherence Scale; QOLHEQ, Quality of Life in Hand Eczema Questionnaire; SD, standard deviation; TSQM, Treatment Satisfaction Questionnaire for Medication.

aNonsystemic treatments included UV therapy, topical corticosteroids always combined with neutral emollients, occasionally with concomitant use of calcineurin inhibitors or tar preparations.
bSystemic treatment included alitretinoin, azathioprine, ciclosporin, dupilumab, methotrexate, and tacrolimus.
cOne patient missing.

*P < .05 (male vs female and systemic vs nonsystemic treatment), **P < .05 and different severity band.
nonsystemic treatment (Table 3). "Global satisfaction" scores for nonsystemic vs different individual systemic treatments are presented in Figure 1. Significantly higher "global satisfaction" scores were found for ciclosporin, alitretinoin, and dupilumab compared with nonsystemic treatment. Figure 2 shows the mean TSQM subdomain scores in different severity groups. Patients with severe/very severe hand eczema had significantly lower subdomain satisfaction scores in "effectiveness" (TSQM score: 47.3, standard deviation [SD]: 14.9) compared with patients with moderate (TSQM score: 55.4, SD: 15.0) or clear/almost clear hand eczema (TSQM score: 66.4, SD: 18.4), \( P < .001 \). Furthermore, TSQM subdomain scores of "global satisfaction" were significantly lower for severe/very severe hand eczema (TSQM score: 80.8, SD: 10.2) compared with moderate (TSQM score: 90.1, SD: 11.0) or clear/almost clear hand eczema (TSQM score: 95.4, SD: 12.1), \( P < .001 \).}

**FIGURE 1** Treatment satisfaction scores (TSQM, range 0-100) for nonsystemic treatment vs different individual systemic treatments. A higher score of the TSQM subdomain "global satisfaction" indicates higher levels of treatment satisfaction, \( P < .05 \). Other treatments are azathioprine, tacrolimus, and UV therapy. TSQM, Treatment Satisfaction Questionnaire for Medication

**FIGURE 2** Treatment satisfaction domain scores (TSQM, range 0-100) in different hand eczema severity groups. Higher scores in the TSQM domains (bars) indicate higher levels of treatment satisfaction. Error bars represent standard deviation, \( P < .05 \) between groups. TSQM, Treatment Satisfaction Questionnaire for Medication
50.4, SD: 14.6) compared with patients with moderate (TSQM score: 61.1, SD: 15.8) or clear/almost clear hand eczema (TSQM score: 69.9, SD: 15.2), P < .001. No significant association between age, hand eczema duration, previous history of systemic treatment, and treatment satisfaction was found.

### 3.3 | Adherence

About 50% of the patients had a medium treatment adherence. In the group of patients with high treatment adherence there were significantly more females than males and significantly more patients using systemic therapy compared with nonsystemic therapy (Table 3). The QOLHEQ and TSQM subdomains scores for different adherence groups are presented in Table 4. A high adherence was significantly associated with a lower QOLHEQ overall score and the QOLHEQ subdomain “emotions.” Moreover, high adherence was associated with higher TSQM “global satisfaction” scores and a higher satisfaction about “effectiveness.”

### 3.4 | Regression analysis

In the univariate analysis (see Data S4), taking the QOLHEQ domain score as the dependent variable, age, duration of hand eczema, education, and adherence were not associated with HRQoL. The multivariate regression model (Table 5) showed that female sex, more severe hand eczema, and lower treatment satisfaction were associated with more impairment of HRQoL (overall QOLHEQ score). This model explained 37% of the variance of the total HRQoL score ($R^2$). Severity was strongly associated with the QOLHEQ subdomain “symptoms.” For the association of “global satisfaction,” the standardized beta was similar for all QOLHEQ subdomains. Female sex was not associated with the QOLHEQ subdomain “emotions.”

### Table 4

Means of health-related quality of life (HRQoL) impairment and treatment satisfaction in different groups of treatment adherence

| Treatment adherence (MMAS-4) | Low (n = 26) | Medium (n = 84) | High (n = 58) |
|-----------------------------|-------------|----------------|-------------|
| HRQoL impairment (QOLHEQ Dutch subdomains), mean (SD)* | | | |
| Symptoms (0-21) | 10.0 (3.2) | 9.5 (3.7) | 8.0 (4.9) |
| Emotions (0-24) | 7.5 (4.6)* | 8.4 (4.8)* | 5.9 (4.9)* |
| Functioning (0-24) | 7.4 (4.9) | 8.2 (4.9) | 6.2 (5.4) |
| Treatment and prevention (0-20) | 8.4 (4.1) | 8.8 (4.1) | 7.1 (5.0) |
| Overall score (0-89) | 32.5 (15.1)* | 34.2 (15.0)* | 26.6 (18.4)* |
| Treatment satisfaction (TSQM subscale 0-100), mean (SD) | | | |
| Effectiveness | 52.2 (17.2)* | 57.7 (17.7)* | 63.1 (19.1)* |
| Side effects | 85.9 (24.6) | 87.1 (21.1) | 67.9 (13.7) |
| Convenience | 61.3 (14.6) | 65.3 (15.2) | 67.9 (13.7) |
| Global satisfaction | 56.1 (13.4)* | 60.9 (16.8)* | 68.5 (17.5)* |

Abbreviations: MMAS-4, 4-item Morisky Medication Adherence Scale; QOLHEQ, Quality of Life in Hand Eczema Questionnaire; SD, standard deviation; TSQM, Treatment Satisfaction Questionnaire for Medication.

*One patient missing.

*P < .05.

### Table 5

Multivariate linear regression analysis assessing factors that would affect the health-related quality of life subdomain scores as the dependent variable

| Variable | Symptoms subdomain $R^2 = 0.41$ | Emotions subdomain $R^2 = 0.26$ | Functioning subdomain $R^2 = 0.33$ | Treatment and prevention subdomain $R^2 = 0.25$ | QOLHEQ overall score $R^2 = 0.37$ |
|----------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Sex (female) | Standardized β | P-value | Standardized β | P-value | Standardized β | P-value | Standardized β | P-value |
| High education | −0.10 | .11 | −0.06 | .37 | − | − | − | − | −0.25 | .80 |
| Current systemic treatment | − | − | − | − | − | − | − | − | 0.05 | .51 |
| Severity | 0.33 | <.001 | 0.16 | .04 | 0.19 | .01 | 0.14 | .08 | 0.22 | <.001 |
| Low adherence | 0.05 | .45 | −0.03 | .63 | 0.01 | .88 | 0.05 | .51 | 0.07 | .31 |
| Higher TSQM global satisfaction score | −0.36 | <.001 | −0.41 | <.001 | −0.43 | <.001 | −0.40 | <.001 | −0.44 | <.001 |

Note: Numbers in bold represent $P < .05$ and standardized β coefficients >0.2.

Note: Variables with a indent (−) had a $P$ value > .2 in the univariate regression analysis and were not suitable for inclusion in the concerning subdomain.

Abbreviations: QOLHEQ, Quality of Life in Hand Eczema Questionnaire; TSQM, Treatment Satisfaction Questionnaire for Medication.
Overall, vesicular hand eczema patients showed a moderately impaired HRQoL, with the highest impairment noted in the QOLHEQ subdomain "symptoms." We demonstrated that more severe hand eczema was associated with more impairment in HRQoL. The association between severity and HRQoL is in line with previous studies that used the Dermatology Life Quality Index to assess HRQoL and included all types of hand eczema. Female sex was associated with more impairment in HRQoL. Female sex is a well-known demographic factor affecting HRQoL. Other studies showed that female patients experienced more HRQoL impairment compared with male patients, or had similar impairment with less severe hand eczema. In the current study "functioning" was particularly affected in females. Female patients probably had more distress related to limitations in work, leisure time, or domestic activities. Previous studies showed a considerable psychosocial burden of hand eczema and underline that anxiety and depression are more common in female patients. In this study we did not find an association between female sex and impairment of HRQoL in the QOLHEQ subdomain "emotions." The regression analyses showed that lower "global satisfaction" was associated with more impairment of HRQoL; the standardized beta was −0.44, which indicates a moderate correlation. In previous studies in patients with gout and hypertension a correlation was also found between these outcomes.

For the total group we have shown that patients were least satisfied with "effectiveness" of treatment. In patients with severe and very severe hand eczema significantly lower satisfaction scores were found for the TSQM subdomains "effectiveness" and "global satisfaction" compared with the other severity groups. Satisfaction about "side effects" and "convenience" were similar in the different severity groups. This implies that effectiveness of treatment is the major factor affecting "global satisfaction," which is supported by previous studies on, for example, patients with psoriasis and lichen sclerosis. These studies found that patients reported treatment effectiveness as the most important factor for overall treatment satisfaction. The group using systemic treatment presented significantly higher satisfaction scores with regard to the "effectiveness," compared with the group without systemic treatment. The "global satisfaction" was significantly higher for alitretinoin, ciclosporin, and dupilumab compared with nonsystemic treatments. In patients with psoriasis data also showed lower "global satisfaction" scores for patients receiving nonsystemic treatment. The use of biologicals for psoriasis resulted in significantly higher for alitretinoin, ciclosporin, and dupilumab compared with nonsystemic treatments. In patients with psoriasis data also showed lower "global satisfaction" scores for patients receiving nonsystemic treatment. The use of biologicals for psoriasis resulted in substantially higher global patient satisfaction scores. Recent observational studies showed promising results regarding the effectiveness of dupilumab in patients with hand eczema and might offer future perspectives for patients with difficult-to-treat vesicular hand eczema.

Treatment adherence was significantly lower in patients receiving nonsystemic treatment compared with systemic treatment. The perception of the relative ineffectiveness and inconvenience of topical treatment and sometimes corticophobia are well known in dermatology. This may hinder adherence and treatment effectiveness. Concerning adherence and QOLHEQ subdomains there was a significant association for the QOLHEQ overall and "emotional" subdomain scores, indicating that high adherence comes in line with less (emotional) HRQoL impairment (Table 4). However, a longitudinal study is needed to verify if less emotional impairment leads to higher adherence or if adherence leads to less emotional problems. A higher medication adherence was also significantly associated with a higher "global satisfaction," while this effect was not seen in the TSQM subdomains "side effects" and "effectiveness."

Some clinical and etiological characteristics need to be highlighted. Of note, half of the patients had ICD during treatment phase (>3 months) and even in the group treated with systemic therapy 40% had an ICD. In our department trained nurse practitioners provide one-to-one patient education for every patient with hand eczema. These are offered personalized glove advice to protect hands from irritant and allergic factors and improve topical treatment compliance. From the high proportion of ICD it can be deduced that despite all efforts it seems impossible for a large proportion of patients to avoid exposure to irritants.

Moreover, we found a high proportion of patients with allergic contact dermatitis (40%), compared with other studies. A possible explanation is the fact that our center is a tertiary reference center for hand eczema. Finally, atopic dermatitis is a well-known risk factor for more severe and chronic hand eczema. The number of patients with atopic hand eczema in this study was in line with previous studies (21.5%–57.5%).

A limitation of our study is the monocentric design in a tertiary referral center. Presumably this patient cohort included more patients with a difficult-to-treat hand eczema in all groups. Nonsystemic treatment was compared with systemic treatment in terms of HRQoL and treatment satisfaction. Patients on systemic treatment are in general more difficult to treat and an effective treatment will influence their HRQoL and treatment satisfaction more strongly. Another limitation of our study is the smaller number of participants treated with systemic medication compared with nonsystemic medication and the small subgroups with individual systemic treatments. The majority of the patients reported relatively high satisfaction scores for systemic treatment. However, patients with higher levels of satisfaction were more likely to continue with treatment and therefore maybe overrepresented. Patients who discontinued treatment because of side effects or inefficacy within 3 months were not included because of our inclusion criteria of treatment longer than 3 months. This is probably one of the reasons for the favorable results for alitretinoin, which was previously demonstrated to be less successful in vesicular hand eczema. If alitretinoin is effective, patients will continue treatment after 3 months.

In conclusion, our results indicate that disease severity affects both HRQoL and treatment satisfaction in patients with vesicular hand eczema. Patients only using topical treatment are less satisfied with their treatment and their treatment adherence is lower. Systemic treatment of severe hand eczema could improve the severity and as a result also HRQoL, treatment satisfaction, and medication adherence.
New systemic treatment options for patients with severe hand eczema, for example, biologicals or small molecules, could possibly contribute to this.

CONFLICTS OF INTEREST
There was no funding and the authors have no conflicts either actual or perceived.

ORCID
Klaziena Politiek  https://orcid.org/0000-0001-6475-6876
Robert F. Ofenloch  https://orcid.org/0000-0002-3532-6110
Ewoud van den Hoed  https://orcid.org/0000-0002-9410-2838
Marie L. A. Schuttelaar  https://orcid.org/0000-0002-0766-4382

REFERENCES
1. Menné T, Johansen JD, Sommerlund M, Veien NK. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis. 2011;65(1):3-12.
2. Cazzaniga S, Ballmer-Weber BK, Gräni N, et al. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. J Eur Acad Dermatol Venereol. 2016;30(4):628-637.
3. Dibenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe chronic hand eczema. J Clin Aesthet Dermatol. 2015;8(11):19-27.
4. Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient - Patient-Centered Outcomes Res. 2019;12(5):445-459.
5. Christoffers W, Coenraads P, Svensson Å et al. Interventions for hand eczema. Cochrane Database of Systematic Reviews. 2019; 4: CD004055. https://doi.org/10.1002/14651858.CD004055.pub2.
6. Agner T, Andersen KE. Brand. 2004;59(1):43-47.
7. Ofenloch RF, Weisshaar E, Dumke AK, Molin S, Dieppen TL, Apfelmacher C. The quality of life in hand eczema questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014;171(2):304-312.
8. Oosterhaven JA, Ofenloch R F, Schuttelaar M-LA. Interpretability of the quality of life in hand eczema questionnaire. J Invest Dermatol. 2019; https://doi.org/10.1016/j.jid.2019.08.450. [Epub ahead of print].
9. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSMQ), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;13:1-13.
10. Tan X, Patel I, Chang J. Review of the four item morisky medication adherence scale (MMAS-4) and eight item morisky medication adherence scale (MMAS-8). Innov Pharm. 2014;5. [Epub ahead of print].
11. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39-48.
12. Oosterhaven JAF, Flach PA, Bultmann U, Schuttelaar MLA. Presenteeism in a Dutch hand eczema population—a cross-sectional survey. Contact Dermatitis. 2018;79(1):10-19.
13. Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV). Richtlijn Handeczem 2019. https://nvdv.nl/professionals/richtlijnen-en-onderzoek/richtlijnen/richtlijn-handeczem. Accessed December 3, 2019.
14. Ariens LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116-126.
15. Coenaards PJ, van der Walle H, Thestrup-Pedersen K, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol. 2005;152(2):296-301.
16. Oosterhaven JA, Ofenloch RF, Schuttelaar M-LA. Validation of the Dutch quality of life in hand eczema questionnaire. Br J Dermatol. 2019; https://doi.org/10.1111/bjd.18558. [Epub ahead of print].
17. Nieminen P, Lehtiniemi H, Vähäkangas K, Huusko A, Rautio A. Standardised regression coefficient as an effect size index in summarising findings in epidemiological studies. Epidemiol Public Health. 2013;10(4):1-15.
18. Cazzaniga S, Ballmer-Weber BK, Gräni N, et al. Chronic hand eczema: a prospective analysis of the Swiss CARPE registry focusing on factors associated with clinical and quality of life improvement. Contact Dermatitis. 2018;79(3):136-148.
19. Marron SE, Tomas-Aragones L, Navarro-Lopez J, et al. The psychosocial burden of hand eczema: data from a European dermatological multicentre study. Contact Dermatitis. 2018;78(6):406-412.
20. Al-Jabi SW, Zyoud SH, Sweileh WM, et al. Relationship of treatment satisfaction to health-related quality of life: Findings from a cross-sectional survey among hypertensive patients in Palestine. Health Expect. 2015;18(6):3336-3348.
21. Khanna PP, Shiozawa A, Walker V, et al. Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Prefer Adherence. 2015;9:971-981.
22. van Crannenburgh OD, Nijland SBW, Lindeboom R, et al. Patients with lichen sclerosus experience moderate satisfaction with treatment and impairment of quality of life: results of a cross-sectional study. Br J Dermatol. 2017;176(6):1508-1515.
23. van Crannenburgh OD, de Korte J, Sprangers MAG, de Rie MA, Smets EMA. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398-405.
24. Callis Duffin K, Yeung H, Takeshita J, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2014;170(3):672-680.
25. Fiorek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review [Internet]. Vol 310. Springer Berlin Heidelberg: Archives of Dermatological Research; 2018:271-319.
26. Hjortberg C, Bergman A, Bjarnason A, et al. Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from finnish and swedish patients with psoriasis. Acta Derm Venereol. 2011;91(4):409-414.
27. Zirwas MJ, Dupilumab for hand eczema. J Am Acad Dermatol. 2018; 79(1):167-169.
28. Oosterhaven JAF, Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study. J Dermatol. 2019;46(8):680-685. https://onlinelibrary.wiley.com/doi/abs/10.1111/1346-8138.14982.
29. Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatol Treat. 2013;24(1):64-69.
30. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. *Br J Dermatol*. 2011;165(4):808-814.

31. Furue M, Onozuka D, Takeuchi S, et al. Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the morisky medication adherence scale-8. *Br J Dermatol*. 2015;172(1):272-275.

32. Brans R, John SM. Clinical patterns and associated factors in patients with hand eczema of primarily occupational origin. *J Eur Acad Dermatol Venereol*. 2016;30(5):798-805.

33. Johansen JD, Hald M, Andersen BL, et al. Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish contact dermatitis Group. *Contact Dermatitis*. 2011;65(1):13-21.

34. Halling-Overgaard AS, Zachariae C, Thyssen JP. Management of atopic hand dermatitis. *Dermatol Clin*. 2017;35(3):365-372.

35. Politiek K, Christoffers WA, Coenraads PJ, Schutteelaar MLA. Alitretinoin and acitretin in severe chronic hand eczema; results from a retrospective daily practice study. *Dermatol Ther*. 2016;29(5):364-371.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

How to cite this article: Politiek K, Ofenloch RF, Angelino MJ, van den Hoed E, Schutteelaar MLA. Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: A cross-sectional study. *Contact Dermatitis*. 2020;82:201–210. [https://doi.org/10.1111/cod.13459](https://doi.org/10.1111/cod.13459)